Developer docs
API playgroundTry for free, no card

Search company profiles

NeuCyte

Full company profile

uuid0005ocv

Namestring
NeuCyte
Legal namestring
NeuCyte, Inc.
Websiteurl
neucyte.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

NeuCyte, Inc. is a privately held, early-stage biotechnology company founded in 2015 and headquartered in Mountain View, California, focused on the early phases of central nervous system (CNS) drug discovery. The company's core offering is the proprietary SynFire Technology platform, which uses human induced pluripotent stem cell (iPSC)-derived neural cells — specifically iNeurons (iNs), iAstrocytes (iA), and iMicroglia (iMG) — to model neurological disease, validate targets, produce custom cells, and screen therapeutic compounds. NeuCyte claims a 100% differentiation success rate from any genetic background and supports phenotypic and target-based screens through electrophysiology (MaxTwo/MaxWell microelectrode arrays), high-content imaging, and 3D neuroimmune microphysiological systems (assembloids).

The company's customer base comprises biopharmaceutical companies as the primary segment, supplemented by academic researchers and rare disease organizations focused on conditions including KIF1A-associated neurological disorder, DLG4-related synaptopathy, KCNT1 epilepsy, Alzheimer's disease, ALS/FTD, and autism. NeuCyte generates revenue through three streams: NIH and foundation research grants, strategic research partnerships with pharma and academic medical centers (UCSF, Mount Sinai), and one-time sales of iPSC-derived cell products via a 2019 distribution agreement with REPROCELL covering North America and Europe. Recent activity (2023–2026) has centered on NIH-funded platform expansion into Alzheimer's high-throughput screening, rare disease foundation grants (KCNT1 2025, KIF1A.ORG 2021), and a January 2026 strategic partnership with Grann Pharmaceuticals for mRNA-based rare neurological disease therapeutics.

Commercial scale remains modest: the company employs 11–50 people, has not disclosed revenue, and has raised approximately $6.7 million in disclosed equity (Series A, 2018) plus targeted NIH and foundation grants. Go-to-market relies on scientific publications, conference presence (Society for Neuroscience, Society of Toxicology, ISSCR, AAIC), webinars, and direct enterprise engagement with pharmaceutical partners, supported by a Scientific Advisory Board drawn from UC Davis, Rutgers, Boston University, and Scripps.

Short descriptiontext

NeuCyte is a privately held biotech that uses proprietary iPSC-derived neural cells (neurons, astrocytes, microglia) on its SynFire platform to support CNS drug discovery, target validation, and disease modeling for biopharmaceutical companies, academic researchers, and rare disease foundations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMountain View, United States
HQ citystring
Mountain View
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC-derived neural cells, CNS drug discovery, neural disease modeling, high-throughput drug screening, iPSC platform technology
Industry2 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
iPSC-based Neuroscience Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1NIH Research Grants
TypeSubscription Recurring
Description

Federal research funding for specific disease areas including Alzheimer's and rare neurological diseases

neucyte.com
2Strategic Research Partnerships
TypeSubscription Recurring
Description

Collaborations with pharmaceutical companies for drug discovery programs, assay development, and therapeutic development

neucyte.com
3iPSC-Derived Cell Products
TypeOne Time License
Description

Sale of SynFire neural cells including iNeurons, iAstrocytes, and iMicroglia to biotech and pharma companies

neucyte.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SynFire
Description

Proprietary iPSC-derived neural cell technology platform for CNS disease modeling, target validation, custom cell production, and compound screening. Includes SynFire iNs (induced neurons), iAstrocytes (iA), and iMicroglia (iMG) products.

neucyte.com
Core offering1 text field

NeuCyte develops and commercializes iPSC-derived human neural cell products and provides CNS drug discovery services built on its proprietary SynFire platform. The company sells iNeurons, iAstrocytes, and iMicroglia as off-the-shelf research reagents and offers custom cell production, assay development, disease modeling, and high-throughput phenotypic drug screening services to pharmaceutical, biotechnology, and academic customers. Its technology is used to model neurological and rare CNS diseases and to identify and validate therapeutic targets and drug candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 100% differentiation success rate into neurons, astrocytes, and microglia from any iPSC background
Product overview1 text field

NeuCyte offers a unified platform combining proprietary SynFire iPSC-derived neural cell products (iNeurons, iAstrocytes, and iMicroglia) with comprehensive services including assay development, functional phenotypic assessment, and custom cell production. The core SynFire Technology platform enables CNS disease modeling, target validation, and high-throughput compound screening using human cell-based models. The company differentiates iPS cells from any background into a range of neural cell types with a 100% success rate, supporting applications in Alzheimer's disease, ALS/FTD, rare diseases, epilepsy, autism, and other neurodegenerative disorders.

Product and service8 records
1SynFire iNeurons
CategoryiPSC-derived neural cell products
Description

iPSC-derived human neurons generated using NeuCyte's proprietary SynFire platform, supplied as off-the-shelf research reagents for neuroscience research, disease modeling, and drug screening applications for pharmaceutical, biotech, and academic customers.

2SynFire iAstrocytes
3SynFire iMicroglia
4Isogenic and Disease Modeling Platform
5Custom iPSC-Derived Cell Production Services
6Assay Development Services
7Functional Phenotypic Assessment (MEA Analysis)
83D Brain Microphysiological Systems
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Strategic partnership to accelerate mRNA-based therapies for rare neurological diseases, combining NeuCyte's iPSC platform with Grann Pharmaceuticals' therapeutic development capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-14
Description

Collaboration on NIH-funded project to develop high-throughput drug screening platform using microfluidics and human cell-based models for Alzheimer's and related dementias. UCSF contributes expertise in neuroscience and ophthalmology research.

3Acoustic Bio
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-08-14
Description

Collaboration on NIH-funded project involving proprietary technologies for microfluidic drug screening platform development. Acoustic-Bio contributes acoustic-based technologies for the platform.

neucyte.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-17
Description

Collaboration to develop iPSC-derived drug screening assays for KIF1A Associated Neurological Disorder, a rare genetic neurological condition.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-19
Description

Collaboration agreement for neurological disease research using iPSC-based models, combining institutional expertise with NeuCyte's platform technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-09-25
Description

Distribution agreement granting REPROCELL rights to distribute NeuCyte products in North America and Europe, expanding market reach for iPSC-derived cell products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Supplies iPSC-derived neural and other cell types, plus assay services, to pharma and academic researchers. Comparable iPSC-based CNS product and services portfolio.

TypeDirect peer
Description

Uses iPSC and synthetic biology to produce defined human cell types at scale, including neural cell types. Direct competitor in iPSC-derived CNS cells and disease modeling.

TypeDirect peer
Description

Provides iPSC-derived neurons and glia for CNS drug discovery and disease modeling. Highly comparable niche player in iPSC neural cell products and assay services.

TypeBroad incumbent
Description

Provides cell culture media, reagents, and iPSC-related products, including neural cell products. Broad incumbent in stem cell and neural cell culture tools that competes with NeuCyte's reagent side.

TypeBroad incumbent
Description

Global CRO offering discovery, in vitro biology, and CNS pharmacology services, including cell-based assays. Broad incumbent competing for outsourced CNS discovery and screening work.

TypeDirect peer
Description

Provides iPSC-derived products and neural cell reagents, and is NeuCyte's distribution partner in NA/Europe. Closest overlap in catalog iPSC neural cells and CNS disease modeling reagents.

TypeBroad incumbent
Description

Large CRO with CNS drug discovery and safety assessment services, including iPSC-based neurotoxicology. Broad incumbent competing for similar pharma discovery and safety services budgets.

TypeDirect peer
Description

Specializes in iPSC-derived cardiomyocytes and neural cells for drug discovery and safety testing. Competes in the same iPSC-based CNS and neurotoxicology assay market.

TypeBroad incumbent
Description

A broad life-sciences incumbent that sells cell culture reagents, iPSC tools, and neurobiology research products. Competes with NeuCyte in adjacent product lines, especially catalog reagents and consumables.

TypeDirect peer
Description

A leading commercial supplier of iPSC-derived cell products, including neural cells, used by pharma and academic researchers. Direct competitor in catalog iPSC neural cells and disease modeling.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuCyte

iPSC-based Neuroscience Drug Discoveryneucyte.com

NeuCyte is a privately held biotech that uses proprietary iPSC-derived neural cells (neurons, astrocytes, microglia) on its SynFire platform to support CNS drug discovery, target validation, and disease modeling for biopharmaceutical companies, academic researchers, and rare disease foundations.

What NeuCyte does

NeuCyte, Inc. is a privately held, early-stage biotechnology company founded in 2015 and headquartered in Mountain View, California, focused on the early phases of central nervous system (CNS) drug discovery. The company's core offering is the proprietary SynFire Technology platform, which uses human induced pluripotent stem cell (iPSC)-derived neural cells — specifically iNeurons (iNs), iAstrocytes (iA), and iMicroglia (iMG) — to model neurological disease, validate targets, produce custom cells, and screen therapeutic compounds. NeuCyte claims a 100% differentiation success rate from any genetic background and supports phenotypic and target-based screens through electrophysiology (MaxTwo/MaxWell microelectrode arrays), high-content imaging, and 3D neuroimmune microphysiological systems (assembloids).

The company's customer base comprises biopharmaceutical companies as the primary segment, supplemented by academic researchers and rare disease organizations focused on conditions including KIF1A-associated neurological disorder, DLG4-related synaptopathy, KCNT1 epilepsy, Alzheimer's disease, ALS/FTD, and autism. NeuCyte generates revenue through three streams: NIH and foundation research grants, strategic research partnerships with pharma and academic medical centers (UCSF, Mount Sinai), and one-time sales of iPSC-derived cell products via a 2019 distribution agreement with REPROCELL covering North America and Europe. Recent activity (2023–2026) has centered on NIH-funded platform expansion into Alzheimer's high-throughput screening, rare disease foundation grants (KCNT1 2025, KIF1A.ORG 2021), and a January 2026 strategic partnership with Grann Pharmaceuticals for mRNA-based rare neurological disease therapeutics.

Commercial scale remains modest: the company employs 11–50 people, has not disclosed revenue, and has raised approximately $6.7 million in disclosed equity (Series A, 2018) plus targeted NIH and foundation grants. Go-to-market relies on scientific publications, conference presence (Society for Neuroscience, Society of Toxicology, ISSCR, AAIC), webinars, and direct enterprise engagement with pharmaceutical partners, supported by a Scientific Advisory Board drawn from UC Davis, Rutgers, Boston University, and Scripps.

NeuCyte firmographics

Firmographics
Name
NeuCyte
Legal name
NeuCyte, Inc.
Website
https://neucyte.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuCyte is a privately held biotech that uses proprietary iPSC-derived neural cells (neurons, astrocytes, microglia) on its SynFire platform to support CNS drug discovery, target validation, and disease modeling for biopharmaceutical companies, academic researchers, and rare disease foundations.
Ownership category
akta.pro rank

NeuCyte industry classification

Industry
Product category
iPSC-based Neuroscience Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • IPSC-derived neural cells
  • CNS drug discovery
  • Neural disease modeling
  • High-throughput drug screening
  • IPSC platform technology

Where NeuCyte is headquartered

Location

Headquarters

HQ city
Mountain View
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuCyte business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. NIH Research Grants: Federal research funding for specific disease areas including Alzheimer's and rare neurological diseases
  2. Strategic Research Partnerships: Collaborations with pharmaceutical companies for drug discovery programs, assay development, and therapeutic development
  3. iPSC-Derived Cell Products: Sale of SynFire neural cells including iNeurons, iAstrocytes, and iMicroglia to biotech and pharma companies

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

NeuCyte product offering

Product offering

Core offering

NeuCyte develops and commercializes iPSC-derived human neural cell products and provides CNS drug discovery services built on its proprietary SynFire platform. The company sells iNeurons, iAstrocytes, and iMicroglia as off-the-shelf research reagents and offers custom cell production, assay development, disease modeling, and high-throughput phenotypic drug screening services to pharmaceutical, biotechnology, and academic customers. Its technology is used to model neurological and rare CNS diseases and to identify and validate therapeutic targets and drug candidates.

Product overview

NeuCyte offers a unified platform combining proprietary SynFire iPSC-derived neural cell products (iNeurons, iAstrocytes, and iMicroglia) with comprehensive services including assay development, functional phenotypic assessment, and custom cell production. The core SynFire Technology platform enables CNS disease modeling, target validation, and high-throughput compound screening using human cell-based models. The company differentiates iPS cells from any background into a range of neural cell types with a 100% success rate, supporting applications in Alzheimer's disease, ALS/FTD, rare diseases, epilepsy, autism, and other neurodegenerative disorders.

Differentiator

Problem solved

Functional benefit

Brands

  • SynFire: Proprietary iPSC-derived neural cell technology platform for CNS disease modeling, target validation, custom cell production, and compound screening. Includes SynFire iNs (induced neurons), iAstrocytes (iA), and iMicroglia (iMG) products.

Products and services

  • SynFire iNeurons iPSC-derived human neurons generated using NeuCyte's proprietary SynFire platform, supplied as off-the-shelf research reagents for neuroscience research, disease modeling, and drug screening applications for pharmaceutical, biotech, and academic customers.
  • SynFire iAstrocytes
  • SynFire iMicroglia
  • Isogenic and Disease Modeling Platform
  • Custom iPSC-Derived Cell Production Services
  • Assay Development Services
  • Functional Phenotypic Assessment (MEA Analysis)
  • 3D Brain Microphysiological Systems

Quantifiable outcome

  • 100% differentiation success rate into neurons, astrocytes, and microglia from any iPSC background

Companies that use NeuCyte

Customer profile

Segments3 records

Ideal customer profiles3 records

NeuCyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NeuCyte partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Grann PharmaceuticalscoreStrategic or Co-development Partner · 13 January 2026Strategic partnership to accelerate mRNA-based therapies for rare neurological diseases, combining NeuCyte's iPSC platform with Grann Pharmaceuticals' therapeutic development capabilities.
  • UCSFcoreStrategic or Co-development Partner · 14 August 2023Collaboration on NIH-funded project to develop high-throughput drug screening platform using microfluidics and human cell-based models for Alzheimer's and related dementias. UCSF contributes expertise in neuroscience and ophthalmology research.
  • Acoustic BiocoreTechnology or Integration · 14 August 2023Collaboration on NIH-funded project involving proprietary technologies for microfluidic drug screening platform development. Acoustic-Bio contributes acoustic-based technologies for the platform.
  • KIF1A.ORGcoreStrategic or Co-development Partner · 17 August 2021Collaboration to develop iPSC-derived drug screening assays for KIF1A Associated Neurological Disorder, a rare genetic neurological condition.
  • Mount SinaicoreStrategic or Co-development Partner · 19 January 2021Collaboration agreement for neurological disease research using iPSC-based models, combining institutional expertise with NeuCyte's platform technology.
  • REPROCELLcoreChannel Partner/ Reseller/ Distributor · 25 September 2019Distribution agreement granting REPROCELL rights to distribute NeuCyte products in North America and Europe, expanding market reach for iPSC-derived cell products.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

NeuCyte competitors and assessment

Company assessment

Direct peers

  • Axol Bioscience: Supplies iPSC-derived neural and other cell types, plus assay services, to pharma and academic researchers. Comparable iPSC-based CNS product and services portfolio.
  • bit.bio: Uses iPSC and synthetic biology to produce defined human cell types at scale, including neural cell types. Direct competitor in iPSC-derived CNS cells and disease modeling.
  • BrainXell: Provides iPSC-derived neurons and glia for CNS drug discovery and disease modeling. Highly comparable niche player in iPSC neural cell products and assay services.
  • REPROCELL: Provides iPSC-derived products and neural cell reagents, and is NeuCyte's distribution partner in NA/Europe. Closest overlap in catalog iPSC neural cells and CNS disease modeling reagents.
  • Ncardia: Specializes in iPSC-derived cardiomyocytes and neural cells for drug discovery and safety testing. Competes in the same iPSC-based CNS and neurotoxicology assay market.
  • Fujifilm Cellular Dynamics (FCDI): A leading commercial supplier of iPSC-derived cell products, including neural cells, used by pharma and academic researchers. Direct competitor in catalog iPSC neural cells and disease modeling.

Broad incumbents

  • STEMCELL Technologies: Provides cell culture media, reagents, and iPSC-related products, including neural cell products. Broad incumbent in stem cell and neural cell culture tools that competes with NeuCyte's reagent side.
  • Pharmaron: Global CRO offering discovery, in vitro biology, and CNS pharmacology services, including cell-based assays. Broad incumbent competing for outsourced CNS discovery and screening work.
  • Charles River Laboratories: Large CRO with CNS drug discovery and safety assessment services, including iPSC-based neurotoxicology. Broad incumbent competing for similar pharma discovery and safety services budgets.
  • Thermo Fisher Scientific (Cell Biology / Bioscience): A broad life-sciences incumbent that sells cell culture reagents, iPSC tools, and neurobiology research products. Competes with NeuCyte in adjacent product lines, especially catalog reagents and consumables.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

NeuCyte social profiles

Digital presence

NeuCyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuCyte leadership team

Management profile

Number of profiles

Profiles3 records

NeuCyte funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuCyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuCyte

What does NeuCyte do?

NeuCyte develops and commercializes iPSC-derived human neural cell products and provides CNS drug discovery services built on its proprietary SynFire platform. The company sells iNeurons, iAstrocytes, and iMicroglia as off-the-shelf research reagents and offers custom cell production, assay development, disease modeling, and high-throughput phenotypic drug screening services to pharmaceutical, biotechnology, and academic customers. Its technology is used to model neurological and rare CNS diseases and to identify and validate therapeutic targets and drug candidates.

Is NeuCyte a public or private company?

NeuCyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was NeuCyte founded?

NeuCyte was founded in 2015. It employs 11 to 50 people.

Where is NeuCyte based?

NeuCyte is headquartered in Mountain View, United States, in the North America region.

How does NeuCyte make money?

Three revenue lines are on record. NIH Research Grants are the primary driver. The others are strategic Research Partnerships and iPSC-Derived Cell Products.

Who are NeuCyte's main competitors?

Direct peers on record are Axol Bioscience, bit.bio, BrainXell, REPROCELL, Ncardia and Fujifilm Cellular Dynamics (FCDI). Broad incumbents are STEMCELL Technologies, Pharmaron, Charles River Laboratories and Thermo Fisher Scientific (Cell Biology / Bioscience).

Does NeuCyte have an API?

No public API is recorded for NeuCyte.

What industry is NeuCyte in?

NeuCyte's product category is iPSC-based Neuroscience Drug Discovery. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
National Center for Biotechnology InformationRePORT ⟩ RePORTERNeuCyte, Inc. received a $500,000 grant from the National Institute on Aging to develop a miniaturized microphysiological system platform for high-throughput screening of Alzheimer's disease therapeutics. The project involves collaboration with UCSF and Acoustic Bio to create assembloid models that better replicate human brain pathology than traditional animal models. Successful completion aims to establish feasibility for commercializing this cost-effective drug discovery tool.NeucyteAwarded NIH GrantNeuCyte, Inc. has been awarded a National Institute of Health Small Business Technology Transfer (STTR) grant to develop a microfluidics-based drug-screening platform for Alzheimer's disease in collaboration with UCSF and Acoustic Bio. The project utilizes NeuCyte’s SynFire® technology to create NeuroImmune Assembloids within an Organ-on-a-Chip system designed to facilitate high-throughput screening for AD/ADRD treatments. This funding supports the advancement of their proprietary mini-brain models for target identification and efficacy testing.PR NewswireNeuCyte and KIF1A.ORG Enter Collaboration AgreementNeuCyte, Inc. announced a research collaboration agreement with KIF1A.ORG to develop treatments for KIF1A-Associated Neurological Disorder (KAND), a progressive and sometimes fatal genetic disorder with no current treatment or cure. The collaboration will leverage NeuCyte's proprietary human iPSC-based in vitro CNS disease modeling technology platform to establish KAND cellular models for academic researchers and biotech companies to screen potential treatments. KIF1A.ORG, a global patient advocacy community dedicated to accelerating research for KAND, seeks to rapidly discover treatments for patients affected by this neurodegenerative condition.PR NewswireNeuCyte and Mount Sinai Enter Collaboration AgreementNeuCyte, Inc. announced a multi-year, milestone-based research collaboration with the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai to study novel autism-associated mutations. The partnership will leverage NeuCyte's proprietary human iPSC-based in vitro CNS disease modeling and assay development platform for preclinical research. The collaboration aims to functionally characterize autism-related genes to advance understanding of the disorder and support therapeutic development.PR NewswireNeuCyte and REPROCELL enter distribution agreement in North America and EuropeNeuCyte, Inc. and REPROCELL, Inc. announced a new distributorship agreement granting REPROCELL customers access to NeuCyte's iPSC-derived glutamatergic and GABAergic induced neurons, supplied with astroglia, media, and supplements in kit formats. The partnership covers North America and Europe, with NeuCyte retaining direct sales in the region while expanding distribution through REPROCELL's global customer network. The companies stated the agreement aims to accelerate adoption of NeuCyte's SynFire® technology for drug discovery research and translational medicine.PR NewswireNeuCyte Licenses Promising Novel Compound for Treatment of Refractory Epilepsy and Related Neurological DisordersNeuCyte, Inc. announced an exclusive worldwide license agreement with Trillium Therapeutics to advance a preclinical compound for treating refractory epilepsy, including Dravet syndrome. The compound demonstrated superior safety and anti-seizure efficacy over benchmark anti-epileptic drugs across eleven animal models and has received NINDS Red Book status. NeuCyte plans to leverage its proprietary iPSC-derived human cell platform to further develop and commercialize this first-in-class therapeutic candidate.PR NewswireNeuCyte Licenses Its Novel Neuronal Programming Technology to Enable Academic ResearchNeuCyte, Inc. announced a license agreement with Boston Children's Hospital granting the hospital a non-exclusive right to manufacture and use transcription factor Ngn2 programmed induced neurons. The technology, originally from Stanford University and further developed by NeuCyte, will be utilized for internal research, teaching, and educational services provided to other academic institutions.PR NewswireNeuCyte Inc. Closes $6.7 Million Series A FinancingNeuCyte, Inc., a neuroscience drug discovery company based in Sunnyvale, California, announced the closing of a $6.7 million Series A financing round, bringing total funding to over $8 million. The round was led by initial investors Cowin Venture and Leaguer Ventures, with proceeds intended to advance NeuCyte's SynFire in vitro CNS drug discovery platform targeting Fragile X Syndrome and other neurological disorders, as well as to establish strategic partnerships for clinical development. The financing represents a routine early-stage venture capital event in the biotechnology sector.